{"id":"zavegepant-100mg-immediate-release-tablet","safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pregabalin","action":"Monitor","effect":"Increased risk of CNS depression"},{"drug":"Opioids","action":"Monitor","effect":"Increased risk of CNS depression"},{"drug":"Benzodiazepines","action":"Monitor","effect":"Increased risk of CNS depression"},{"drug":"CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Avoid","effect":"Increased zavegepant plasma concentrations"},{"drug":"CYP3A4 inducers (e.g., rifampin, carbamazepine)","action":"Avoid","effect":"Decreased zavegepant plasma concentrations"}],"contraindications":["Hypersensitivity to zavegepant or any component of the formulation","Hypersensitivity to any component of the formulation of zavegepant or other triptans","Ischemic heart disease, including angina pectoris, myocardial infarction, or Prinzmetal's angina","Wolff-Parkinson-White syndrome or other cardiac conduction abnormalities","Cerebrovascular disorders such as hemiplegic or basilar migraine, or a history of stroke or transient ischemic attack","Peripheral vascular disease","Ischemic bowel disease","Uncontrolled hypertension","Migraine patients with other underlying conditions that may predispose them to experience cerebrovascular events (e.g., diabetes mellitus, hyperlipidemia, hypertension, smoking, obesity, family history of stroke, transient ischemic attack, or cerebrovascular disease","Severe renal impairment (CrCl < 15 mL/min)","Severe hepatic impairment (Child-Pugh Class C)"]},"company":"Pfizer Inc.","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=zavegepant-100mg-immediate-release-tablet","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:40.182907+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:45.503923+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:40.257093+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=zavegepant-100mg-immediate-release-tablet","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:45.814870+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Calcitonin gene-related peptide type 1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:47.219184+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650220/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:46.885310+00:00"}},"allNames":"zavegepant 100mg immediate release tablet","timeline":[],"aiSummary":"Zavegepant is a migraine treatment developed by Pfizer Inc. It is an immediate release tablet available in 100mg dosage. Zavegepant is used for the acute treatment of migraine with or without aura in adults. The exact mechanism of action is not specified. However, it is likely to target a specific molecular pathway involved in migraine. Zavegepant has the potential to provide relief for individuals experiencing migraines. Further research and clinical trials are needed to fully understand its effects and benefits.","brandName":"Zavegepant 100mg immediate release tablet","isGeneric":true,"mechanism":{"target":"calcitonin gene-related peptide receptor (CGRPR)","novelty":"first-in-class","modality":"small molecule","drugClass":"calcitonin gene-related peptide receptor antagonist","explanation":"","oneSentence":"","technicalDetail":"Zavegepant's mechanism of action is not fully understood, but it is believed to target the calcitonin gene-related peptide receptor (CGRPR). This receptor plays a crucial role in the development and progression of migraines. By blocking the CGRPR, Zavegepant may help to reduce the frequency and severity of migraines. Further research is needed to confirm its exact mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=zavegepant-100mg-immediate-release-tablet","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:48.494330+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"competitors":[{"name":"Lasmiditan 100mg tablet","company":"Eli Lilly and Company","advantage":"Lasmiditan is a serotonin 5-HT1F receptor agonist, similar to Zavegepant, but with a different mechanism of action.","genericName":"Lasmiditan"},{"name":"Rimegepant 75mg tablet","company":"Eli Lilly and Company","advantage":"Rimegepant is a calcitonin gene-related peptide receptor antagonist, similar to Zavegepant, but with a different mechanism of action.","genericName":"Rimegepant"},{"name":"Ubrogepant 100mg tablet","company":"Allergan","advantage":"Ubrogepant is a calcitonin gene-related peptide receptor antagonist, similar to Zavegepant, but with a different mechanism of action.","genericName":"Ubrogepant"}],"genericName":"zavegepant-100mg-immediate-release-tablet","indications":{"approved":[{"name":"Acute treatment of migraine with or without aura in adults","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"_emaApprovals":[{"date":"","name":"Zavegepant 100mg immediate release tablet","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":false,"chemblId":"CHEMBL4650220","moleculeType":"Small molecule","molecularWeight":"675.28"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4650220"},"_offLabelChecked":true,"publicationCount":0,"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_genericFilersChecked":true,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"trialDetails":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:48.494330+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}